Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial
Open Access
- 2 May 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 30 (13) , 1666-1673
Abstract
Increases in body weight (BW) are important determinants for hospitalization in ambulatory patients with heart failure (HF), but have not yet been explored in patients hospitalized for worsening HF. We explore the relationship between change in BW after hospitalization for worsening HF and risk for repeat hospitalization and mortality in the EVEREST trial. The EVEREST trial randomized 4133 patients hospitalized for worsening HF and low ejection fraction (≤40%) to tolvaptan, a vasopressin antagonist, or placebo. Following discharge, BW was assessed at 1, 4, and 8 weeks, and every 8 weeks thereafter. A time-dependent Cox proportional Hazard model explored the relationship between change in BW at 60, 120, and 180 days from discharge and the risks of HF hospitalization, cardiovascular (CV) hospitalization, and all-cause mortality. For subjects re-hospitalized for heart failure at 60, 120, and 180 days after discharge, mean BW increase prior to the event was 1.96, 2.07, and 1.97 kg, respectively, compared with 0.74, 0.90, and 1.04 kg in patients without re-hospitalization (P < 0.001 all groups). A similar pattern was observed with CV hospitalization. However, increases in BW were not predictive of all-cause mortality. Increases in BW after hospitalization for worsening HF was predictive of repeat hospitalization events, but not mortality in the post-discharge period.Keywords
This publication has 28 references indexed in Scilit:
- Heart Disease and Stroke Statistics—2009 UpdateCirculation, 2009
- Heart Failure-Related Hospitalization in the U.S., 1979 to 2004JACC, 2008
- Randomized Controlled Trial of an Implantable Continuous Hemodynamic Monitor in Patients With Advanced Heart FailureJACC, 2008
- Patterns of Weight Change Preceding Hospitalization for Heart FailureCirculation, 2007
- Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart FailureThe EVEREST Clinical Status TrialsJAMA, 2007
- Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart FailureThe EVEREST Outcome TrialJAMA, 2007
- Preventing Osteoporosis-Related Fractures: An OverviewThe American Journal of Medicine, 2006
- Acute Heart Failure SyndromesCirculation, 2005
- Rationale and Design of the Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST)Journal of Cardiac Failure, 2005
- Decompensated heart failure: symptoms, patterns of onset, and contributing factorsThe American Journal of Medicine, 2003